Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

14.88 +0.07 (+0.47%)
Official Closing Price Updated: 4:10 PM EDT, Sep 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Takeda Pharmaceutical Ltd ADR

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?
Tech layoffs are in the news, but life sciences companies seem to be doing better. 
Via The Motley Fool
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
The company says it plans soon to present Phase 2 results and its Phase 3 study design. 
Via Investor's Business Daily
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
Via Benzinga
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result... 
Via Benzinga
Why Puma Biotechnology's Shares Jumped 20% on Monday
It may have benefited from positive news about another company's drug candidate. 
Via The Motley Fool
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
Via Benzinga
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
Via Benzinga
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
Via Benzinga
2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade
Is now the time to load up on these high-yielding investments? 
Via The Motley Fool
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close. 
Via The Motley Fool
7 Dividend Stocks to Sell Pronto Before a Painful Downturn
Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield. 
Via InvestorPlace
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
These stocks all pay far higher than the S&P 500 average dividend yield of 1.8%. 
Via The Motley Fool
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Via Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
7 Stocks Under $15 to Buy and Hold Forever
For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul. 
Via InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate
The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of... 
Via Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Via Benzinga
Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26
CNBC The Aviation Sector Is Slammed By Sky-High Rents 
Via Benzinga
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried
Shares hit their lowest point since November on the FDA's decision in HAE. 
Via Investor's Business Daily
Peering Into Takeda Pharmaceutical's Recent Short Interest
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has risen 18.18% since its last report. The company recently reported that it has 4.18 million shares sold... 
Via Benzinga
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome... 
Via Benzinga
Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents
Via Benzinga
Peering Into Takeda Pharmaceutical's Recent Short Interest
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 15.38% since its last report. The company recently reported that it has 3.29 million shares sold short, which... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.